On May 11-12, 2021, Guangzhou DiQi Pharmaceuticals Co., Ltd participated in the Greater Bay Area (Guangzhou) Biomedical Innovators Summit. Dr. Liu Feng, CEO of Guangzhou DiQi Pharmaceuticals Co., Ltd, delivered a keynote speech on the application of biodegradable materials in Class II innovative drugs. The company also showcased its latest research achievements and samples, including poly(lactic-co-glycolic acid) (PLGA), long-acting implants, ocular implants, and sustained-release microspheres. These innovations garnered significant attention and interest from attendees, particularly those involved in technology and investment sectors. Many attendees expressed astonishment and admiration upon learning that DiQi's implant can be injected into the eyeball and sustain release for six months.

An interesting incident also unfolded at the booth. A technical expert from a participating pharmaceutical company noted that several exhibitors, similar to DiQi, were engaged in technology development, and expressed interest in learning about the advantages of DiQi's platform. Just then, a client with whom we had previously collaborated approached to discuss business. He picked up a sample displayed on the table and praised, “The quality of your PLGA is truly excellent!” He then inquired, “We'd also like samples of your PLGA-PEG. Do you have any in stock?” High-quality products and services are the cornerstone of DiQi's growth. After all, no amount of praise can match the endorsement of satisfied customers!

DiQi's competitive edge lies in its decade-long commitment to continuous improvement and innovation. The company has achieved independent development and intellectual property protection for a series of key excipients and high-end formulations, forging a distinctive path in premium pharmaceutical formulations. Its flagship technology—long-acting microsphere formulations—meets critical clinical needs and is experiencing rapid sales growth in the domestic market, drawing significant industry attention. On the day of the conference, Mininet reported on the recent explosive growth of China's microsphere market! (Link provided at the end of the article)

Leveraging robust R&D capabilities and a quality management system, Guangzhou DiQi has established six proprietary formulation technology platforms: targeted nanomedicines, long-acting injectable microspheres, polyethylene glycol-modified formulations, oral controlled-release formulations, generic drug consistency evaluation, and high-end excipients.

Digi leverages its formulation technology platform to provide domestic and international innovative drug and generic drug companies with comprehensive product development and manufacturing services, global regulatory submissions, and technical consulting services.